PROCEED VENTRAL PATCH

K061533 · ETHICON, Inc. · FTL · Dec 11, 2006 · General, Plastic Surgery

Device Facts

• Record ID: K061533
• Device Name: PROCEED VENTRAL PATCH
• Applicant: ETHICON, Inc.
• Product Code: FTL · General, Plastic Surgery
• Decision Date: Dec 11, 2006
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 878.3300
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

PROCEED Ventral Patch is intended for the repair of hernias or other abdominal fascial defects that require the addition of a reinforcing or bridging material to obtain the desired surgical result. PROCEED Ventral Patch is also indicated for the repair of tissue deficiencies caused by trocar use.

Device Story

PROCEED Ventral Patch is a self-expanding, partially absorbable, laminate mesh implant used for hernia repair and abdominal fascial defect closure. The device consists of multiple layers: oxidized regenerated cellulose (ORC) fabric, PROLENE Soft Mesh, two absorbable polydioxanone polymer rings, VICRYL Mesh, polydioxanone polymer film, and polyester suture. It is intended for surgical use by physicians to reinforce or bridge tissue deficiencies. The device provides mechanical support to the abdominal wall; it is implanted during surgical procedures to facilitate tissue repair and healing.

Clinical Evidence

No clinical data provided. Evidence consists of bench testing and animal testing to evaluate functional performance and biological reactivity. Biological reactivity was assessed per ISO 10993-1 and found acceptable.

Technological Characteristics

Self-expanding, partially absorbable laminate mesh. Materials: oxidized regenerated cellulose (ORC), PROLENE Soft Mesh (polypropylene), polydioxanone polymer rings/film, VICRYL Mesh (polyglactin 910), and polyester suture. Sterile, implantable device. Biological reactivity assessed per ISO 10993-1.

Indications for Use

Indicated for patients requiring repair of hernias, abdominal fascial defects, or tissue deficiencies resulting from trocar use, where reinforcement or bridging material is necessary.

Regulatory Classification

Identification

Surgical mesh is a metallic or polymeric screen intended to be implanted to reinforce soft tissue or bone where weakness exists. Examples of surgical mesh are metallic and polymeric mesh for hernia repair, and acetabular and cement restrictor mesh used during orthopedic surgery.

Predicate Devices

• PROLENE Soft Mesh
• PROCEED Mesh
• BARD Ventralex & Small Ventralex Hernia Patch
• VICRYL Mesh
• ETHIBOND Polyester Suture

Submission Summary (Full Text)

{0}------------------------------------------------

KU61533

12

Summary of Safety and Effectiveness

Information supporting claims of substantial equivalence, as defined under the Federal Food, Drug and Cosmetic Act, respecting safety and effectiveness is summarized below.

#### Submitted by:

Bryan A. Lisa Sr. Regulatory Affairs Associate Ethicon, Inc., A Johnson & Johnson Company Route 22 West, PO Box 151 Somerville, NJ 08876

## Name/Classification of Device:

Class II in 21 CFR § 878.3300, Surgical Mesh (FTL)

## Trade Name:

PROCEED* Ventral Patch

## Predicate Devices:

PROLENE* Soft Mesh PROCEED* Mesh BARD Ventralex & Small Ventralex Hernia Patch VICRYL* Mesh ETHIBOND* Polyester Suture

#### Statement of Intended Use:

PROCEED Ventral Patch is intended for the repair of hernias or other abdominal fascial defects that require the addition of a reinforcing or bridging material to obtain the desired surgical result.

PROCEED Ventral Patch is also indicated for the repair of tissue deficiencies caused by trocar use.

#### Device Description:

The proposed PROCEED Ventral Patch (PVP) is a self-expanding, partially absorbable, laminate mesh device that is designed for the repair of hernias and other fascial deficiencies such as those caused by trocar use. The mesh device is comprised of several layers: an absorbable fabric of oxidized regenerated cellulose (ORC), PROLENE* Soft Mesh, two absorbable polydioxanone polymer rings, VICRYL* Mesh, polydioxanone polymer film, and polyester suture.

#### Summary of Technological Characteristics of New Device to Predicate Devices:

The modified device has similar technological characteristics as the predicate devices. Like currently marketed devices, it is a sterile, mesh implant intended for the repair of hernias or abdominal fascial defects. Like several

{1}------------------------------------------------

of the currently marketed devices, the proposed device is made of nonabsorbable and absorbable polymers. The polymers used are identical to those found in PROCEED Mesh and VICRYL Mesh, currently marketed by Ethicon, Inc.

K061533

2/2

## Performance Data:

Biological reactivity of the materials has been assessed using methods specified in ISO Standard 10993-1, and the material was found to be acceptable for its intended use. Results of functional performance testing (bench and animal testing) indicate that the proposed device meets or exceeds all functional requirements.

## Conclusions:

Based on the similarities to the predicate devices identified in this submission, we conclude that the modified device is substantially equivalent to the predicate devices under the Federal Food, Drug, and Cosmetic Act.

* Trademark of Ethicon, Inc.

{2}------------------------------------------------

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle or bird-like figure with its wings spread, positioned to the right of a circular border. Encircling the bird is the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" in capital letters.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Ethicon, Inc. % Mr. Bryan A. Lisa Senior Regulatory Affairs Associate Route 22 West, P.O. Box 151 Somerville, New Jersey 08876

Re: K061533

Trade/Device Name: PROCEED Ventral Patch Regulation Number: 21 CFR 878.3300 Regulation Name: Surgical mesh Regulatory Class: II Product Code: FTL Dated: November 21, 2006 Received: November 22, 2006

Dear Mr. Lisa:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

OEC I 1 2006

{3}------------------------------------------------

Page 2 - Mr. Bryan A. Lisa

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at [phone]. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours

for
Mark N. Melkerson

Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

## Indications for Use

# 510(k) Number (if known): K06 / 533

Device Name: PROCEED* Ventral Patch

Indications for Use:

PROCEED Ventral Patch is intended for the repair of hernias or other abdominal fascial defects that require the addition of a reinforcing or bridging material to obtain the desired surgical result.

PROCEED Ventral Patch is also indicated for the repair of tissue deficiencies caused by trocar use.

*Trademark.

(21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Division of General, Restorative, and Neurological Devices

**510(k) Number** L061532